What is the antibiotic of choice for acute Hidradenitis suppurativa presenting to the emergency department?

Antibiotic of Choice for Acute Hidradenitis Suppurativa in the Emergency Department

For acute HS presenting to the emergency department, prescribe oral clindamycin 300 mg twice daily combined with rifampin 300 mg twice daily for 10-12 weeks as first-line therapy for moderate disease, or oral tetracyclines (doxycycline 100 mg twice daily or lymecycline) for at least 12 weeks for mild disease. 1, 2

Treatment Algorithm Based on Disease Severity

Mild Disease (Hurley Stage I)

• First-line: Oral tetracyclines (doxycycline 100 mg twice daily or lymecycline) for minimum 12 weeks 1, 2
• Consider treatment breaks to assess ongoing need and limit antimicrobial resistance 2

Moderate Disease (Hurley Stage II) or Tetracycline Failure

• First-line: Clindamycin 300 mg twice daily PLUS rifampin 300 mg twice daily for 10-12 weeks 1, 2
• This combination shows 71-93% response rates across 187 patients in systematic reviews 1
• Can be repeated intermittently as needed 1

Severe Disease (Hurley Stage III) or Acute Flares

• Rescue therapy: IV ertapenem as bridge to long-term therapy 1
• Adjunctive: Prednisone pulse or taper (0.5-1 mg/kg daily) for rapid symptom control while bridging to definitive therapy 1
• Effect is rapid and substantial but side effects limit prolonged use 1

Critical ED Management Considerations

What NOT to Do

• Do NOT prescribe clindamycin monotherapy - increases Staphylococcus aureus resistance rates 1
• Do NOT perform routine incision and drainage - this is appropriate for simple abscesses but not standard HS management 3
• Do NOT prescribe short antibiotic courses - minimum 10-12 weeks required for combination therapy 1, 2

Current ED Prescribing Patterns (What's Actually Happening vs. What Should Happen)

Real-world data shows ED providers most commonly prescribe:

1. Trimethoprim/sulfamethoxazole (44.5%)
2. Beta-lactams (33.2%)
3. Clindamycin monotherapy (27.7%)

This pattern does NOT align with guideline recommendations 4. The ED is significantly more likely to prescribe antibiotics overall (74.7% vs 49% in ambulatory settings) but often selects inappropriate agents 4.

Adjunctive ED Interventions

Intralesional Corticosteroids

• Triamcinolone 10 mg/mL (0.2-2.0 mL) injected into individual inflamed lesions 1
• Provides significant pain reduction within 1 day 1
• Reduces erythema, edema, suppuration, and lesion size 1
• Use for carefully selected individual lesions during acute phase 2

Pain Management

• Address pain aggressively - this is a critical quality-of-life issue 2
• Measure pain using validated instruments 2

Essential ED Discharge Planning

Mandatory Referrals

• Dermatology referral - only 3.4% of pediatric HS ED encounters receive dermatology consultation, but this is essential 3
• Smoking cessation services if relevant 2
• Weight management services if relevant 2

Patient Education

• Provide written information about HS 2
• Explain this is a chronic inflammatory disease, not a simple infection
• Dressings for suppurating lesions 2

Screening for Comorbidities

• Depression and anxiety 2
• Cardiovascular risk factors (diabetes, hypertension, hyperlipidemia, central obesity) 2
• Inflammatory bowel disease if persistent GI symptoms 2

Common Pitfalls to Avoid

1. Treating HS like a simple skin abscess - I&D alone has high recurrence and doesn't address underlying inflammation 3

2. Prescribing clindamycin monotherapy - this increases antibiotic resistance without optimal efficacy 1

3. Short antibiotic courses - HS requires minimum 10-12 weeks of combination therapy, not 7-10 day courses 1, 2

4. Missing the diagnosis - HS is often misdiagnosed as recurrent furunculosis or simple abscesses 3

5. Failing to refer to dermatology - ED management is only acute stabilization; long-term control requires specialist care 3

Evidence Quality Note

The North American guidelines 1 and British guidelines 2 represent the highest quality evidence available (2019), though most recommendations are based on Level II-III evidence and expert consensus rather than large RCTs. The clindamycin-rifampin combination has the strongest evidence base for ED-initiated therapy with response rates of 71-93% 1.